Last reviewed · How we verify
Anti-IL12/23 or anti-IL23 - Ustekinumab
Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of inflammatory and autoimmune responses.
Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of inflammatory and autoimmune responses. Used for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Anti-IL12/23 or anti-IL23 - Ustekinumab |
|---|---|
| Sponsor | University of Calgary |
| Drug class | Monoclonal antibody; IL-12/IL-23 inhibitor |
| Target | IL-12 p40 subunit (shared with IL-23) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Ustekinumab binds to the p40 subunit shared by both IL-12 and IL-23, preventing these interleukins from activating T cells and other immune cells that drive inflammation. By inhibiting these pathways, it reduces pathogenic Th1 and Th17 cell differentiation and proliferation, thereby suppressing the inflammatory cascade underlying autoimmune and inflammatory diseases.
Approved indications
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reactions
- Infections (serious)
Key clinical trials
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (PHASE4)
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: